Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Investing Activities (2022 - 2025)

Axsome Therapeutics' Cash from Investing Activities history spans 4 years, with the latest figure at -$71000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 136.67% year-over-year to -$71000.0; the TTM value through Dec 2025 reached -$480000.0, down 77.78%, while the annual FY2025 figure was -$480000.0, 77.78% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$71000.0 at Axsome Therapeutics, down from -$58000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$7000.0 in Q4 2023 and bottomed at -$53.2 million in Q2 2022.
  • The 4-year median for Cash from Investing Activities is -$80500.0 (2023), against an average of -$3.4 million.
  • The largest YoY upside for Cash from Investing Activities was 99.75% in 2023 against a maximum downside of 462.12% in 2023.
  • A 4-year view of Cash from Investing Activities shows it stood at -$181000.0 in 2022, then skyrocketed by 96.13% to -$7000.0 in 2023, then crashed by 328.57% to -$30000.0 in 2024, then tumbled by 136.67% to -$71000.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Cash from Investing Activities are -$71000.0 (Q4 2025), -$58000.0 (Q3 2025), and -$13000.0 (Q2 2025).